- Details
- Alicia Morgans interviews Pierre Blanchard about testosterone recovery after prostate cancer treatment. Dr. Blanchard explains that testosterone recovery can take 6 to 24 months with LHRH agonists and 1 to 6 months with antagonists. Factors affecting recovery include patient age, baseline testosterone, ADT duration, and comorbidities. He emphasizes the importance of realistic expectations and ackn...
|
- Details
- Diane Newman interviews Siobhan Sutcliffe about a project funded as part of the White House Moonshot Initiative. This project aims to gather more data to support PSA-based risk-stratified screening for prostate cancer. By using a man's PSA value, the research seeks to determine whether he might develop clinically significant prostate cancer that could potentially shorten his lifespan. The study in...
|
- Details
- Irene Burger discusses the significant impact of PSMA PET in diagnosing high-risk localized prostate cancer. Dr. Burger describes the rapid adoption of this technology in Switzerland, emphasizing its enhanced sensitivity over traditional imaging since its integration in 2016. Dr. Burger highlights the broad acceptance and crucial insights from significant studies, such as the proPSMA trial, which...
|
- Details
- Although there has been a single retrospective study published of salvage SBRT after brachytherapy, re-irradiation post-brachytherapy (PMID: 36739178) is largely unstudied. Here we present the first prospective trial for salvage SBRT paradigm after brachytherapy, NCT03253744. Biographies: Krishnan R. Patel, MD, Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD Related Content...
|
- Details
- Jeffrey Tosoian presents a new tool in prostate cancer diagnosis with the development and validation of an 18-gene urine test designed to identify clinically significant prostate cancer published in JAMA Oncology. This research, supported by the Prostate Cancer Foundation (PCF) and the NCI Early Detection Research Network, introduces a novel approach to enhancing the accuracy of prostate cancer de...
|
- Details
- Alicia Morgans hosts Daniel Barocas and Bashir Al Hussein Al Awamlh to discuss findings from the CEASAR study published in JAMA, which explores long-term quality of life outcomes for men with localized prostate cancer. Initiated by Dave Penson, this longitudinal study aims to enhance shared decision-making in treatment by providing data on the side effects of various prostate cancer treatments. Fo...
|
- Details
- At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the PRIMARY trials' findings that combining PSMA PET with MRI significantly improves the accuracy of detecting clinically significant malignancies. Dr. Emmett introduces the PRIMARY score for interpreting PSMA PET results and discusses ongoin...
|
- Details
- Matthew Cooperberg introduces the inaugural patient-oriented journal club for patients diagnosed with prostate cancer. This patient journal club aims to highlight prostate cancer research, selected trials, and pivot to open discussion between expert clinicians and patients. The 15-year update from the ProtecT trial, led by Professors Freddie Hamdy and Jenny Donovan is the selected trial for this s...
|
- Details
- In this Prostate Cancer Patient Journal Club discussion, Matthew Cooperberg and Jenny Donovan address quality-of-life outcomes from the ProtecT trial's surveillance group. Jenny notes that those who did not progress avoided radical treatment impacts, with no significant quality of life difference compared to radically treated patients. Group discussion includes side effects and global variability...
|
- Details
- Alicia Morgans talks with Mack Roach about his research in radiation oncology and urology. Dr. Roach discusses his involvement in studies like RTOG 75-06, 86-10, and 85-31, focusing on hormones and radiation in prostate cancer. He shares insights from his analysis of pre-treatment testosterone data from 2,400 patients, revealing that age over 70 correlates with better prostate cancer-specific outc...
|
